PubRank

A Langleben

Author PubWeight™ 14.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999 1.63
2 Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996 1.31
3 Pulmonary blastoma: case report of a patient with a 7-year remission and review of chemotherapy experience in the world literature. Cancer 1998 1.25
4 Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995 1.04
5 Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999 0.89
6 Expression of common acute lymphoblastic leukemia-associated antigen on germ cell tumor. Am J Med 1986 0.88
7 Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000 0.87
8 Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Crit Rev Oncol Hematol 1999 0.84
9 A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 2008 0.81
10 A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997 0.80
11 Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 1999 0.79
12 Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin Invest Med 1990 0.79
13 High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study. Can J Neurol Sci 2000 0.78
14 Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial. Cancer 2001 0.77
15 High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can J Neurol Sci 1993 0.76
16 Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrow. Acta Haematol 1988 0.76
17 Double antibody radioimmunoassay for monitoring metastatic breast cancer. Br J Cancer 1988 0.75
18 Autologous bone marrow transplantation using unfractionated cells without rate-controlled freezing in hydroxyethyl starch and dimethyl sulfoxide. Ann N Y Acad Sci 1983 0.75
19 Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. Neurosurg Focus 1998 0.75
20 Case report: management of methotrexate toxicity in an anephric patient. Clin Invest Med 1982 0.75
21 A phase I study of escalating interferon alpha-2a combined with 5-fluorouracil and leucovorin in patients with gastrointestinal malignancies. Acta Oncol 1993 0.75
22 A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma. Cancer 1999 0.75
23 Phase II study of tiazofurin in gliomas in adults. A National Cancer Institute of Canada study. J Neurooncol 1993 0.75
24 Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 2004 0.75
25 T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease. Clin Invest Med 1988 0.75
26 A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1995 0.75